IPP Bureau
GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative
By IPP Bureau - March 27, 2025
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Innovaoleo launches Omega 3 Star for food, nutraceutical and pet nutrition
By IPP Bureau - March 27, 2025
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Merck and Zebra Technologies collaborate to create safety and traceability solutions
By IPP Bureau - March 27, 2025
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital
By IPP Bureau - March 27, 2025
The freshly infused capital will primarily be deployed towards expansion and research & development
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries
By IPP Bureau - March 27, 2025
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Cadila launches Cadilose for constipation and hepatic encephalopathy
By IPP Bureau - March 26, 2025
Glenmark launches nutrition program to fight malnutrition in Philippines
By IPP Bureau - March 26, 2025
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Alembic Pharma and Amlan International partner to advance poultry health in India
By IPP Bureau - March 26, 2025
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Merck inks $200 million deal for Hengrui's midstage heart disease drug
By IPP Bureau - March 26, 2025
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Wipro announces AI Agent Solutions across healthcare industry
By IPP Bureau - March 25, 2025
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda
By IPP Bureau - March 25, 2025
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes
By IPP Bureau - March 24, 2025
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Briefs: Alembic Pharmaceuticals and Shelter Pharma
By IPP Bureau - March 24, 2025
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG
By IPP Bureau - March 24, 2025
The products will be manufactured in Goa India and marketed & distributed in Australian markets
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
By IPP Bureau - March 24, 2025
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
